InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+6.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by PAUL STEVEN M, Chairman & CEO. Officer active across 4 companies, notably Karuna Therapeutics, Inc.. Cumulatively, 12 filings have been published. Split: 3 buys · 0 sell. Total volume traded: €213k. Activity tracked since 17 August 2021. The latest transaction was filed on 18 March 2024 (Disposition). Regulator: SEC (Form 4). The full history is free.
Declarations12 total
2,046 shares@ US$330.004.1% of flowCommon StockSEC:0001140361-24-013933:0
47,378 shares@ US$315.1891.6% of flowCommon StockSEC:0000950170-24-024999:0
27,510 shares@ US$7.271.2% of flowCommon StockSEC:0000950170-24-020397:0
804 shares@ US$317.141.6% of flowCommon StockSEC:0000950170-24-013963:0
106,485 shares0Common StockSEC:0000899243-23-004747:0
5 shares@ US$38.167571.1% of flowCommon StockSEC:0001562180-22-007940:0
15,000 shares@ US$11.330.0004% mcap100.0% of flowCommon StockSEC:0001735276-22-000039:0
1 shares@ US$43.3650.0% of flowCommon StockSEC:0001562180-21-007019:0
1 shares@ US$43.3614.4% of flowCommon StockSEC:0001562180-21-007019
1,183 shares@ US$105.6350.0% of flowCommon StockSEC:0001593968-21-001992:0
Ideal exit: 14 May 2022 (T+270)
1,183 shares@ US$105.630.7% of flowCommon StockSEC:0001593968-21-001992
Ideal exit: 14 May 2022 (T+270)
10,000 sharesCommon StockSEC:0001104659-16-090139:0
Ideal exit: 10 Oct 2016 (T+270)
12 of 12 declarations
About PAUL STEVEN M
Mr. Paul Steven M. is Chairman & CEO and Board Member of Karuna Therapeutics, Inc., Sage Therapeutics, Inc., and ALNYLAM PHARMACEUTICALS, INC. He leads the operations and strategy of these companies, bringing his expertise in the pharmaceutical sector.
